Differential kinetics of phenytoin in elderly patients

Drugs and Aging

Volumn 15, Issue 3, 1999, Pages 235-250

  Bachmann, Kenneth A ^a   Belloto Jr , Robert J ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; CARBAMAZEPINE; CIMETIDINE; CIPROFLOXACIN; CYTOCHROME P450; FLUCONAZOLE; FLUOXETINE; ISONIAZID; KETOCONAZOLE; OMEPRAZOLE; PENTOBARBITAL; PHENOBARBITAL; PHENYTOIN; PLASMA PROTEIN; RIFAMPICIN; SERTRALINE; SULFONAMIDE; THEOPHYLLINE; TICLOPIDINE; VALPROIC ACID;

AGED; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG SAFETY; ELDERLY CARE; FOCAL EPILEPSY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER METABOLISM; MICHAELIS CONSTANT; NYSTAGMUS; ORAL DRUG ADMINISTRATION; OXIDATION; POLYPHARMACY; PRIORITY JOURNAL; REVIEW; SOMNOLENCE; TONIC CLONIC SEIZURE; VERTIGO;

AGE FACTORS; AGED; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; LIVER; PHENYTOIN; PROTEIN BINDING;

EID: 0032853391     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199915030-00006     Document Type: Review

References (122)

1. Lindley C. Tully M, Paramsothy V, et al. Inappropriate medication is a major cause of adverse drug reactions in elderly patients. Age Ageing 1992; 21: 294-300
2. Cadieux R. Drug interactions in the elderly: how multiple drug use increases risk exponentially. Postgrad Med 1989; 86: 179-86
3. Pourmand R. Seizures and epilepsy in older patients: evaluation and management. Geriatrics 1996; 51: 39-52
4. Stolarek IH, Brodic AF, Brodic MJ. Management of seizures in the elderly: a survey of UK geriatricians. J R Soc Med 1995; 88: 686-9
5. Doecke CJ, Veronese ME, Pond SM, et al. Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. Br J Clin Pharmacol 1991; 31: 125-30
6. Levy RH. Cytochrome P450 isozymes and antiepiteptic drug interactions. Epilepsia 1995; 36: Suppl. 5: S8-13
7. Glazko AJ. Diphenylhydantoin metabolism. Drug Metab Dispos 1973; 5: 711-4
8. Fritz S, Lindner W, Roots I, et al. Stereochemistry of aromatic phenytoin hydraxylation in various drug hydroxylation phenotypes in humans. J Pharmacol Exp Ther 1987; 241: 615-22
9. Srivastava P, Yun CH, Beaune P, et al. Separation of human liver microsomal tolbutamide hydroxylase and (S)-mephenytoin 4'-hydroxylase cytochrome P-450 enzymes. Mol Pharmacol 1991; 40: 69-79
10. Richardson TH, Johnson EF. The CYP2C subfamily. In: Ioannides C. editor. Cytochromes P450: metabolic and toxicological aspects. Boca Raton (FL): CRC Press, 1996: 161-81
11. Veronese M, Doecke C, Mackenzie P, et al. Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochem J 1993; 289: 533-8
12. Veronese M, Mackenzie P, Doecke C, et al. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem Biophys Res Commun 1991; 175: 1112-8
13. Tassaneeyakl W, Veronese M, Birkett D, et al. Co-regulation of phenytoin and tolbutamide metabolism in humans. Br J Clin Pharmacol 1992; 34: 494-8
14. Bajpai M, Roskos L, Shen D, et al. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab Dispos 1996; 24: 1401-3
15. Inoue K, Yamazaki H, Imiya K, et al. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl-hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics 1997; 7: 103-13
16. Meyer U, Zanger U. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 1997; 37: 269-96
17. Odani A, Hashimoto Y, Otsuki Y, et al. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Clin Pharmacol Ther 1997; 62: 287-92
18. Durnas C, Loi CM, Cusack BJ. Hepatic drug metabolism and aging. Clin Pharmacokinet 1990; 19: 359-89
19. LeCouteur D, McLean A. The aging liver drug clearance and an oxygen diffusion barrier hypothesis. Clin Pharmacokinet 1998; 34: 359-73
20. Wood A, Vestal R, Wilkinson G, et al. Effect of aging and cigarette smoking on antipyrine and indocyanine green elimination. Clin Pharmacol Ther 1979; 26: 16-20
21. Wynne H, Cope L, Mutch E, et al. The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology 1989; 9: 297-301
22. Tsujimoto G, Hashimoto K, Hoffman BB. Pharmacokinetic and pharmacodynamic principles of drug therapy in old age: Pt 1. Int J Clin Pharmacol Ther Toxicol 1989; 27: 13-26
23. Kampmann J, Sinding J, Moller-Jorgensen I. Effect of age on liver function. Geriatrics 1975; 30: 91-5
24. Birnbaum L. Pharmacokinetic basis of age-related changes in sensitivity to toxicants. Annu Rev Pharmacol 1991; 31: 101-28
25. Kamataki T, Maeda K, Shimado M, et al. Age related alteration in the activities of drug-metabolizing enzymes and contents of sex-specific forms of cytochrome P450 in liver microsomes from male and female rats. J Pharmacol Exp Ther 1985; 233: 222-8
26. Sotaniemi E, Arranto A, Pelkonen O, et al. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathalogic conditions. Clin Pharmacol Ther 1997; 61: 331-9
27. Kinirons M, Crome P. Clinical pharmacokinetic considerations in the elderly: an update. Clin Pharmacokinet 1997; 33: 302-12
28. Hunt C, Westerkam W, Stave G. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 1992; 44: 275-83
29. Vestal R. Aging and determinants of hepatic drug clearance. Hepatology 1989; 9: 331-4
30. LeConteur D. The physiology of the aging liver. Brisbane: The University of Queensland, 1994
31. Posner J, Danhof M, Teunissen M, et al. The disposition of antipyrine and its metabolites in young and elderly healthy volunteers. Br J Clin Pharmacol 1987; 24: 51-5
32. Richens A. A study of the pharmacokinetics of phenytoin (diphenylhydantoin) in epileptic patients, and the development of a nomogram for making dose increments. Epilepsia 1975; 16: 627-46
33. Bohinsky RC. Modern concepts in biochemistry. 2nd ed. Boston (MA): Allyn and Bacon. Inc., 1976
34. Wilkinson GN. Statistical estimations in enzyme kinetics. Biochem J 1961; 80: 324-32
35. Grasela TH, Sheiner LB, Rambeck B, et al. Steady-state pharmacokinetics of phenytoin from routinely collected patient data. Clin Pharmacokinet 1983; 8: 355-64
36. Roc DJ, Karol MD. Averaging pharmacokinetic parameter estimates from experimental studies: statistical theory and application. J Pharm Sci 1997; 86: 621-4
37. Mawer GE, Mullen PW, Rodgers M, et al. Phenytoin dose adjustment in epileptic patients. Br J Clin Pharmacol 1974; 1: 163-8
38. Murphy JE, Bruni J, Stewart RB. Clinical utility of six methods of predicting phenytoin doses and plasma concentrations. Am J Hosp Pharm 1981; 38: 348-54
39. Hudson S, Farquhar D, Thompson D, et al. Phenytoin dosage individualization-five methods compared in elderly. J Clin Pharm Ther 1990; 15: 25-34
40. Ismail R, Rahman AFA, Chand P. Pharmacokinetics of phenytoin in routine clinic patients in Malaysia. J Clin Pharm Ther 1994; 19: 245-8
41. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm 1980; 8: 553-71
42. Yukawa E, Higuchi S, Aoyama T. Population pharmacokinetics of phenytoin from routine clinical data in Japan: an update. Chem Pharm Bull 1990; 38: 1973-6
43. Odani A, Hashimoto Y, Takayanagi K, et al. Population pharmacokinetics of phenytoin in Japanese patients with epilepsy: analysis with a dose-dependent clearance model. Biol Pharm Bull 1996; 19(3): 444-8
44. Chan E, Ti TY, Lee HS. Population pharmacokinetics of phenytoin in Singapore Chinese. Eur J Clin Pharmacol 1990; 39(2): 177-81
45. Hashimoto Y, Koue T, Otsuki Y, et al. Simulation for population analysis of Michaelis-Menten elimination kinetics. J Pharmacokinet Biopharm 1995; 23 (2): 205-16
46. Vozeh S, Muir K, Sheiner L, et al. Predicting individual phenytoin dosage. J Pharmacokinet Biopharm 1981; 9: 131-46
47. Schumitzky A. The nonparametric maximum likelihood approach to pharmacokinetic population analysis. In: Proceedings of the 1993 Western Simulation Multiconference: simulation for healthcare: 1993 Jan 17-20: La Jolla (CA). San Diego (CA): Society for Computer Simulation International, 1993; 95-100
48. Mallet A, A maximum likelihood estimation method for random coefficient regression models. Biometrika 1986; 73: 645-56
49. Schumitzky A. Nonparametric EM algorithms for estimating prior distributions. Appl Math Comput 1991; 45: 143-57
50. Houghton GW, Richens A, Leighton M. Effect of age, height, weight and sex on serum phenytoin concentration in epileptic patients. Br J Clin Pharmacol 1975; 2: 251-6
51. Crowley J, Cusack B, Jue S, et al. Aging and drug interactions: II. Effect of phenytoin and smoking on the oxidation of theophylline and cortisol in healthy men. J Pharmacol Exp Ther 1988; 245: 513-23
52. Bach B, Hansen J, Kampmann J, et al. Disposition of antipyrine and phenytoin correlated with age and liver volume in man. Clin Pharmacokinet 1981; 6: 389-96
53. Bauer L, Blouin R. Age and phenytoin kinetics in adult epileptics. Clin Pharmacol Ther 1982; 31: 301-4
54. Quintana E, Maiques J, Ibanez E, et al. Parametros farmacocineticos de tenitoina en monoterapia en una poblacion geriatrica. Hosp Pharm 1995; 19: 24-5
55. Ludden TM, Allen JP, Valutsky WA, et al. Individualization of phenytom dosage regimens. Clin Pharmacol Ther 1977; 31: 301-4
56. Verbeeck RK, Cardinal JA, Wallace SM. Effect of age and sex on the plasma binding of acidic and basic drugs. Eur J Clin Pharmacol 1984; 27: 91-7
57. Estruch JA, Galdames DP, Martinetti AK, et al. Phenytoin pharmacokinetics in young and old adults [in Spanish]. Rev Med Chil 1992; 120: 1106-9
58. Schmidt-Nielsen K. Energy metabolism, body size, and problems of sealing. Fed Proc 1970; 9: 1524-32
59. Klausen B, Toubro S, Astruo A. Age and sex effects on energy expenditure. Am J Clin Nutr 1997; 65: 895-907
60. Driessen O, Treuren L, Meijer JWA, et al. Distribution of drugs over whole blood: II. The transport function of whole blood for phenytoin. Ther Drug Monit 1989; 11: 390-400
61. Kramer RL, Richens A. Two dimensional immunoelectrophoresis of human serum proteins for the investigation of protein binding of drugs. Br J Pharmacol 1972; 45: 184P-5
62. Pike E, Kierult P, Skuterud B, et al. Drug binding in sera deficient in lipoproteins. albumin, or orosomucoid. Br J Clin Pharmacol 1983; 16: 233-9
63. Lunde PKM, Rane A, Yaffe SJ, et al. Plasma protein binding of diphenylhydantoin in man: interaction with other drugs and the effects of temperature and plasma dilution. Clin Pharmacol Ther 1970; 11: 846-55
64. Patterson M, Heazelwood R, Smithurst B, et al. Plasma protein binding of phenytom in the aged: in vivo studies. Br J Clin Pharmacol 1982; 13: 423-5
65. Bendei AD, Post A, Meier JP, et al. Plasma protein binding of drugs as function of age in adult human subjects. J Pharm Sci 1975; 64: 1711-3
66. Reidenburg N, Draver D. Alteration of drug-protein binding in renal disease. Clin Pharmacokinet 1984; 9 Suppl. 1: 18-26
67. Dasgupta A. Increased free phenytoin concentrations in predialysis serum compared to postdialysis serum in patients with uremia treated with hemodialysis: role of uremic compounds Am J Clin Pathol 1992; 98: 19-25
68. Olsen GD, Bennett WM, Porter GA. Morphine and phenytoin binding to plasma proteins in renal and hepatic failure. Clin Pharmacol Ther 1975; 17: 677-84
69. Kober A, Jennor A, Sjöholm I. Differentiated effects of liver enthosis on the albumin binding sites for diazepam, salicylic acid and wartarm. Biochem Pharmacol 1978; 27: 2729-35
70. Williams R, Blaschke TF, Meffin P, et al. Influence of acute viral hepatitis on disposition and plasma binding of tolbutamide. Clin Pharmacol Ther 1977; 21: 301-9
71. Lai C, Moore P, Quon CY. Binding of fosphenytoin, phosphate ester pro drug of phenytom, to human serum proteins and competitive binding with carbamazepine, diazepam, phenobarbital, phehylbutazone, phenytoin, valproic acid or warfarin. Res Commun Mol Pathol Pharmacol 1995; 88: 51-62
72. Hayes MJ, Langman MJS, Short AH. Changes in drug metabolism with increasing age: 2. Phenytoin clearance and protein binding. Br J Clin Pharmacol 1975; 2: 73-9
73. Winter ME, Tozer TN, Phenytoin. In: Evans WE, Schentag JJ, Jusko WK. editors. Applied pharmacokinetics: principles of therapeutic drug monitoring. Vancouver (WA): Applied Therapeutics. Inc., 1992: 25-1-14
74. Mattson RH, Cramer J, Williamson PD, et al. Valproic acid in epilepsy: clinical and pharmacological effects. Ann Neurol 1978; 3: 20-5
75. Kober A, Olsson Y. Sjöholm I. Binding of drugs to human serum albumin XIV: the theoretical basis for the interaction between phenytoin and valproate. Mol Pharmacol 1980; 18: 237-42
76. Haidukewych D, Rodin E, Zielinski J. Derivation and evaluation of an equation for prediction of free phenytoin concentration in patients co-medicated with valproic acid. Ther Drug Monit 1989; 11: 134-9
77. Lai ML, Huang JD. Dual effect of valproic acid on the pharmacokinetics of phenytoin. Biopharm Drug Dispos 1993; 14: 365-70
78. Kutt H, Verebely K. Metabolism of diphenylhydantoin by rat liver microsomes: I. Characteristics of the reaction. Biochem Pharmacol 1970; 19: 675-86
79. Brennan R, Dehejia H, Kutt H, et al. Diphenylhydantoin intoxication attendant to slow inactivation of isoniazid. Neurology 1970; 20: 687-93
80. Miller R, Porter J, Greenblatt DJ. Clinical importance of the interaction of phenytoin and isoniazid. Chest 1979; 75: 356-8
81. Zand R, Nelson S, Slattery J, et al. Inhibition and induction of cytochrome P4502E1-catalyzed oxidation by isoniazid in humans. Clin Pharmacol Ther 1993; 54: 142-9
82. Hansen J, Kampmann J, Siersbaek-Nielson K, et al. The effect of different sulfonamides on phenytoin metabolism in man. Acta Med Scand 1979; 624 Suppl.: 106-10
83. Brian W, Srivastava P, Umbenhauer D, et al. Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in Saccaromyces cerevisiae. Biochemistry 1989; 28 (12): 4993-9
84. Miners J, Smith K, Robson R, et al. Tolbutamide hydroxylation by human liver microsomes: kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochem Pharmacol 1988; 37: 1137-44
85. Jones B, Hawksworth G, Horne V, et al. Putative active site model for CP2C9 (tolbutamide hydroxylase). In: Lechner M, editor. Cytochrome P450 biochemistry biophysics and molecular biology. Paris: John Libbey Eurotext, 1994: 523-5
86. Zielinski J, Haidukewych D, Leheta B. Carbamazepine-phenytoin interaction: elevation of plasma phenytoin concentrations due to carbamazepine comedication. Ther Drug Monit 1985; 7: 51-3
87. Kerr B, Thumel K, Wurden C, et al. Human liver carbamazepine metabolism: role of CYP3A4 and CYP2C8 in 10-11-epoxide formation. Biochem Pharmacol 1994; 47: 1969-79
88. Zielinski J, Haidukewych D. Dual effects of carbamazepine-phenytoin interaction. Ther Drug Monit 1987; 9: 21-3
89. Fleishaker JC, Pearson LK, Peters GR. Phenytoin causes a rapid increase in 6-beta-hydroxycortisol urinary excretion in humans: a putative measure of CYP3A induction. J Pharm Sci 1995; 84: 292-4
90. Backman J, Olkkola K, Ojala M, et al. Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. Epilepsia 1996; 37: 253-7
91. Nolan Jr P, Erstad B, Hoyer G, et al. Steady-state interaction between amiodarone and phenytoin in normal subjects. Am J Cardiol 1990; 65: 1252-7
92. Fabre G, Julian B, Saint-Aubert B, et al. Evidence for CYP3-mediated N-deethylation of amiodarone in human liver microsomal fractions. Drug Metab Dispos 1993; 21: 978-85
93. Ha H, Candinas R, Stieger B, et al. Interaction between amiodarone and lidocaine. J Cardiovasc Pharmacol 1996; 28: 533-9
94. Frigo G, Lecchini S, Caravaggi M, et al. Reduction in phenytoin clearance caused by cimetidine. Eur J Clin Pharmacol 1983; 25: 135-7
95. Bartle W, Walker S, Shapero T. Dose-dependent effect of cimetidine on phenytoin kinetics. Clin Pharmacol Ther 1983; 33: 649-55
96. Nation R, Evans A, Milne R. Pharmacokinetic drug interactions with phenytoin: Pt I. Clin Pharmacokinet 1990; 18: 37-60
97. Knodell R, Browne D, Gwozdz G, et al. Differential inhibition of individual human liver cytochromes P-450 by cimetidine. Gastroenterology 1991; 101: 1680-91
98. Sadeque AJM, Fisher MB, Korzekwa KR, et al. Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene valproic acid. J Pharmacol Exp Ther 1997; 283 (2): 698-703
99. Prichard P, Walt R, Kithingman G, et al. Oral phenytoin pharmacokinetics during omeprazole therapy. Br J Clin Pharmacol 1987; 24: 543-5
100. Yamazaki H, Inoue K, Shaw P, et al. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples J Pharmacol Exp Ther 1997; 283: 434-42
101. Ieiri I, Mamiya K, Urae A, et al. Stereoselective 4'-hydroxylation of phenytoin: relationship to (S)-mephenytoin polymorphism in Japanese. Br J Clin Pharmacol 1997; 43: 441-5
102. von Moltke L, Greenblatt D, Shader R. Clinical pharmacokinetics of antidepressants in the elderly: therapeutic implications. Clin Pharmacokinet 1993; 24: 141-60
103. Beers M Explicit criteria for determining inappropriate medication use by the elderly: an update. Arch Intern Med 1997; 157: 1531-6
104. Shader R, Greenblatt D, von Moltke L. Fluoxetine inhibition of phenytoin metabolism. J Clin Psychopharmacol 1994; 14: 375-6
105. Richelson E. Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. Mayo Clin Proc 1997; 7: 835-47
106. Schmider J, Greenblatt D, von Moltke L, et al. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin p-hydroxylation. Br J Clin Pharmacol 1997; 44: 495-8
107. Haselberger M, Freedman L, Tolbert S. Elevated serum phenytoin concentrations associated with coadministration of sertraline. J Clin Psychopharmacol 1997; 17: 107-9
108. Rapeport W, Muirhead D, Williams S, et al. Absence of effect of sertraline on the pharmacokinetics and pharmacodynamics of phenytoin. J Clin Psychiatry 1996; 57 (1 Suppl.): 24-8
109. Touchette M, Chandrasekar P, Milad M, et al. Contrasting effects of fluconazole and ketoconazole on phenytoin and testosterone disposition in man. Br J Clin Pharmacol 1992; 34: 75-8
110. Blum R, Wilton J, Hilligoss D, et al. Effect of fluconazole on the disposition of phenytoin. Clin Pharmacol Ther 1991; 49: 420-5
111. Rindone J. Bryan G. Phenytoin toxicity associated with ticlopidine administration [letter]. Arch Intern Med 1996; 156: 1113
112. Riva R, Cerullo A, Albani F, et al. Ticlopidine impairs phenytoin clearance: a case report. Neurology 1996; 46: 1172-3
113. Donahue S, Abernethy D. Ticlopidine inhibition of steady state phenytoin metabolism in humans [abstract]. Clin Pharmacol Ther 1998; 63: 183
114. Donahue S, Flockhart D, Abernethy D, et al. Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19, Clin Pharmacol Ther 1997; 62: 572-7
115. Conney A. Pharmacological implications of microsomal enzyme induction. Pharmacol Rev 1967; 19: 317-65
116. Rendic S, Di Carlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 1997; 29: 413-580
117. Browne T, Szabo G, Evans J, et al. Phenobarbital docs not alter phenytoin steady-state serum concentration or pharmacokinetics. Neurology 1988; 38: 639-42
118. Yoshida N, Oda Y, Nishi S, et al. Effect of barbiturate therapy on phenytoin pharmacokinetics. Crit Care Med 1993; 21: 1514-22
119. Kutt H. Interactions between anticonvulsants and other commonly prescribed drugs. Epilepsia 1984; 25 (2 Suppl.): S118-31
120. Bachmann K, Jauregui L. Use of single sample clearance estimates of cytochrome P450 substrates to characterize hepatic CYP status in vivo. Xenobiotica 1993; 23: 307-15
121. Kay L, Kampmann J, Svendsen T, et al. Influence of rifampicin and isoniazid on the kinetics of phenytoin. Br J Clin Pharmacol 1985; 20: 323-6
122. Loi CM, Parker B, Cusack BJ, et al. Aging and drug interactions: III. Individual and combined effects of cimetidine and ciprofloxacin on theophylline metabolism in heathy male and female nonsmokers. J Pharmacol Exp Ther 1997; 280: 627-37